Juan José Lahuerta
Hospital Universitario 12 de Octubre (Madrid) · Hospital 12 de Octubre · Hospital Universitario 12 de Octubre
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Juan José Lahuerta as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07045909 · Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)PETHEMA Foundation · recruiting · De Novo Multiple Myeloma, Anitocabtagene Autoleucel · study chair
- Ph2NCT06574126 · Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple MyelomaPETHEMA Foundation · recruiting · High Risk Smoldering Multiple Myeloma · study chair
- Ph2NCT05849610 · Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple MyelomaPETHEMA Foundation · active not recruiting · High-Risk de Novo Multiple Myeloma · study chair
- Ph3NCT05558319 · NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-IberdomidePETHEMA Foundation · recruiting · Newly Diagnosed Multiple Myeloma · study chair
- Ph2NCT05527340 · Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.PETHEMA Foundation · active not recruiting · Multiple Myeloma · study chair
- Ph2NCT01325896 · Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · unknown · Multiple Mieloma · principal investigator
- Ph3NCT00480363 · QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of ProgressionPETHEMA Foundation · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 13:33 UTC. The ranking covers the 200 most relevant of 57 PubMed records, and a shared surname and initials can bring in a namesake. All 57 on PubMed
- Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.N Engl J Med · 2013452 citationsRCR 11.9
- 392 citationsRCR 11.2
- 377 citationsRCR 8.7
- 377 citationsRCR 9.5
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.Blood · 2014343 citationsRCR 9.6
- 294 citationsRCR 6.7
- 246 citationsRCR 6.8
- 221 citationsRCR 5.0
- 196 citationsRCR 7.3
- Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.J Clin Oncol · 2011179 citationsRCR 4.8